Progressing its R&D pact inked with Editas Medicine Inc. in March 2017, Allergan PLC on Aug. 7 confirmed it would take up the option of developing and marketing a candidate from the US-based CRISPR specialist to treat a retinal degenerative disorder, Leber congenital amaurosis (LCA).
The Irish-headquartered pharma said it would co-develop and co-commercialize EDIT-101 globally specifically for the treatment of LCA10. Also, Editas for...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
